Pulmonary embolism

American Regent Introduces Potassium Phosphates, USP; FDA-Approved and "AP" Rated¹

Retrieved on: 
星期四, 十月 19, 2023
Cardiac arrest, ECG, Injection, Seizure, Arrhythmia, Nephrocalcinosis, Hypercalcaemia, Infant, Kidney, Continuity, Risk, Hyperkalemia, Death, Parenteral nutrition, Child, Potassium, Lactation, Thrombosis, Acute kidney injury, Milk, Tetany, Toxicity, Phosphate, Patient, Central nervous system, Bolus, Hyperphosphatemia, Hypophosphatemia, Hypotension, Hypocalcemia, Tubing (recreation), Pulmonary embolism, Use, Aluminium, Administration, Late preterm infant, QT, Calcium, Ketoacidosis, Phosphorus, Birth control, Medical device, Pharmaceutical industry, Magnesium deficiency

In addition, inappropriate intravenous administration of undiluted or insufficiently diluted potassium phosphates as a rapid "IV push" has resulted in cardiac arrest, cardiac arrhythmias, hypotension, and death.

Key Points: 
  • In addition, inappropriate intravenous administration of undiluted or insufficiently diluted potassium phosphates as a rapid "IV push" has resulted in cardiac arrest, cardiac arrhythmias, hypotension, and death.
  • Vein Damage and Thrombosis: Potassium Phosphates Injection must be diluted and administered in intravenous fluids or used as an admixture in parenteral nutrition.
  • You are encouraged to report adverse drug events to American Regent, Inc. at 1-800-734-9236 or to the FDA by visiting www.fda.gov/medwatch or calling 1-800-FDA-1088.
  • You are encouraged to report adverse drug events (ADEs) to American Regent:
    ADEs may also be reported to the FDA:

Inovia Vein Specialty Centers Commemorates World Thrombosis Day: Spreading Awareness on Deep Vein Thrombosis (DVT)

Retrieved on: 
星期三, 十月 11, 2023
General Health, Health, Surgery, Cardiology, Pain, Knowledge, Common, Tenderness, Prevalence, Vein, DVT, Travel, System, Swelling, Education, SE, Deep vein thrombosis, Pulmonary embolism, Red, Leg, Learning, Skin, Patient, Nursing, Birth control, Poultry farming, Tourism, Bend

As the world comes together to observe World Thrombosis Day on October 13th, 2023, Inovia Vein Specialty Centers proudly joins the global campaign to raise awareness about the prevalence and risks associated with Deep Vein Thrombosis (DVT).

Key Points: 
  • As the world comes together to observe World Thrombosis Day on October 13th, 2023, Inovia Vein Specialty Centers proudly joins the global campaign to raise awareness about the prevalence and risks associated with Deep Vein Thrombosis (DVT).
  • Inovia Vein Specialty Centers is dedicated to educating our communities about DVT, its signs, symptoms, and treatment options.
  • Deep Vein Thrombosis (DVT) occurs when blood clots form in the deep veins of the legs or other parts of the body.
  • About Inovia Vein Specialty Centers: Inovia Vein Specialty Centers is a leading provider of vein care services, committed to delivering top-quality care for patients with venous diseases.

World Thrombosis Day encourages public to "Move Against Thrombosis" to celebrate 10 years of raising awareness worldwide

Retrieved on: 
星期五, 十月 13, 2023
Foot, Coronary thrombosis, ISTH, Thrombosis, Death, International Society, Tenderness, Chest pain, Pelvis, Uterus, Organization, VTE, DVT, Hospital, Travel, Pregnancy, Calf, Heart rate, Cancer, Movement, Blood, Thrombus, Pulmonary embolism, International Society on Thrombosis and Haemostasis, Patient, Walking, Leg, Deep vein thrombosis, Vein, Ankle, Risk, Birth control

World Thrombosis Day engages 5,000 partner organizations from 120 countries to advance understanding of the treatment and prevention of blood clots.

Key Points: 
  • World Thrombosis Day engages 5,000 partner organizations from 120 countries to advance understanding of the treatment and prevention of blood clots.
  • For its 10th anniversary year, the campaign encourages people to Move Against Thrombosis with simple movements to increase blood flow.
  • Thrombosis can develop in, or travel to, blood vessels throughout the body, often causing symptoms that can be mistaken for other conditions.
  • Incorporating movement in blood clot prevention inspired World Thrombosis Day's Move Against Thrombosis theme.

World Thrombosis Day encourages public to "Move Against Thrombosis" to celebrate 10 years of raising awareness worldwide

Retrieved on: 
星期五, 十月 13, 2023
Foot, Coronary thrombosis, ISTH, Thrombosis, Death, International Society, Tenderness, Chest pain, Pelvis, Uterus, Organization, VTE, DVT, Hospital, Travel, Pregnancy, Calf, Heart rate, Cancer, Movement, Blood, Thrombus, Pulmonary embolism, International Society on Thrombosis and Haemostasis, Patient, Leg, Deep vein thrombosis, Vein, Ankle, Risk, Birth control

World Thrombosis Day engages 5,000 partner organizations from 120 countries to advance understanding of the treatment and prevention of blood clots.

Key Points: 
  • World Thrombosis Day engages 5,000 partner organizations from 120 countries to advance understanding of the treatment and prevention of blood clots.
  • For its 10th anniversary year, the campaign encourages people to Move Against Thrombosis with simple movements to increase blood flow.
  • Thrombosis can develop in, or travel to, blood vessels throughout the body, often causing symptoms that can be mistaken for other conditions.
  • Incorporating movement in blood clot prevention inspired World Thrombosis Day's Move Against Thrombosis theme.

Ontogen Medtech Secures Illinois $50k SBIR Matching Grant to Advance Partnership with Flow Medical on Groundbreaking Pulmonary Embolism Catheter Device

Retrieved on: 
星期四, 十月 5, 2023
Partnership, CDT, Disease, Pulmonary embolism, Entrepreneurship, Embolism, Illinois Department of Veterans' Affairs, University of Chicago Medical Center, Commerce, University, Principal, Patient, Overalls, Illinois Department of Commerce and Economic Opportunity, PE, Pulmonary artery, SBIR, Medical device

The SBIR Phase I grant matching program was announced in 2022 by Governor JB Pritzker for companies within the State of Illinois.

Key Points: 
  • The SBIR Phase I grant matching program was announced in 2022 by Governor JB Pritzker for companies within the State of Illinois.
  • "We are deeply honored to have been selected as recipients of the SBIR matching grant from the state of Illinois," said Tyler Panian, Principal and Co-Founder of Ontogen Medtech.
  • "This grant not only reaffirms our dedication to advancing medical technologies within the state but also recognizes the significance of our collaboration with Flow Medical.
  • "We are thrilled to continue our partnership with Ontogen Medtech and appreciate the support from the State of Illinois to advance our pursuit of the catheter device's potential in revolutionizing pulmonary embolism treatment," said Jennifer Fried, CEO at Flow Medical.

New Clinical Data Supports Viz.ai Solution for Improved Pulmonary Embolism Detection and Care Coordination

Retrieved on: 
星期四, 九月 21, 2023
Nursing, Cardiology, Technology, Health, Health Technology, Medical Devices, Apps, Applications, Software, Artificial Intelligence, Hospitals, Surgery, PE, Use, Workflow, Temple University, Pulmonary embolism, VPS Healthcare, Research, TriHealth, PERT, Viz, Triage, Patient, Treatment, Algorithm, Artificial intelligence, AI, Detection, CTPA, Dentistry, Medical device, Medicine

Viz.ai, the leader in AI-powered disease detection and intelligent care coordination, today announced new clinical data supporting advancements in pulmonary embolism (PE) detection.

Key Points: 
  • Viz.ai, the leader in AI-powered disease detection and intelligent care coordination, today announced new clinical data supporting advancements in pulmonary embolism (PE) detection.
  • Two studies have demonstrated the real-world clinical efficacy of Viz.ai's PE Module to quickly and accurately identify PE and associated right heart strain, accelerate care coordination, and improve healthcare workflow efficiency.
  • Pulmonary embolism is a severe medical condition, which affects around 900,000 people in the U.S. every year, and often challenging to diagnose and treat due to overlapping symptoms with other diseases.
  • The study found that, across 100 retrospectively-collected chest CTPA images, Viz PE demonstrated a sensitivity of 91.1% and specificity of 100.0%.

Aidoc's AI Solution for Pulmonary Embolism Clinically Proven to Reduce Hospital Stay Duration and Improves Patient Access to Treatment

Retrieved on: 
星期五, 九月 22, 2023
Learning, Medicine, CT, University of Texas Medical Branch, University, Workflow, Peer review, Pulmonary embolism, EMR, University of Chicago, Intelligence, Research, PERT, Chicago Department of Public Health, Embolism, Radiology, UTMB, Triage, Patient, Jamaica Hospital Medical Center, PES, Artificial intelligence, AI, ICU, Health, Candace Pert, Nursing, Medical imaging, Medical device, Aidoc

AUSTIN, Texas, Sept. 22, 2023 /PRNewswire/ -- Groundbreaking research in the advancement of AI-driven pulmonary embolism (PE) care was unveiled yesterday evening during the 9th Annual Pulmonary Embolism Symposium. Research from three leading institutions utilizing Aidoc's PE AI solution demonstrated immense clinical value in reducing mean hospital length of stay, improving patient access, and correctly alerting care teams of suspected PEs with potential for advanced interventions.

Key Points: 
  • Research from three leading institutions utilizing Aidoc's PE AI solution demonstrated immense clinical value in reducing mean hospital length of stay, improving patient access, and correctly alerting care teams of suspected PEs with potential for advanced interventions.
  • The three studies highlighted the care advantages of utilizing Aidoc in the management of acute pulmonary embolisms, including numerous patient outcome benefits.
  • Key findings from the studies presented include:
    "Proving the robustness of any AI solution hinges on the application of scientific rigor and the scrutiny of peer review.
  • These studies illustrate the ongoing evolution of Aidoc's AI-powered PE solution from an algorithm to enterprise-wide platform used by Pulmonary Embolism Response Teams (PERTs) across entire health systems.

Global Clot Management Devices Market Share, Trends, Opportunities, Competition, and Forecasts, 2018-2023 & 2023-2028 - ResearchAndMarkets.com

Retrieved on: 
星期二, 九月 12, 2023
Medical Devices, Health, Surgery, General Health, Pharmaceutical, Cardiology, PE, Regional basketball competitions in Spain, Hip, Prevalence, Pulmonary embolism, Stroke, Tetraplegia, Cardiovascular disease, DVT, Ageing, Cancer, Research, Competition, Compound annual growth rate, Thrombectomy, Incidence, Hospital, AIDS, Deep vein thrombosis, Growth, Diagnosis, WHO, Smoking, Knee, World Health Organization, Medical device, Video game, Dietary supplement, Birth control

The global clot management devices market is projected to experience consistent growth with a steady Compound Annual Growth Rate (CAGR) throughout the forecast period from 2024 to 2028.

Key Points: 
  • The global clot management devices market is projected to experience consistent growth with a steady Compound Annual Growth Rate (CAGR) throughout the forecast period from 2024 to 2028.
  • Advancements in clot management device technologies aimed at enhancing the diagnosis and treatment of conditions like stroke, coupled with the increasing preference for minimally invasive medical procedures, are driving the demand for clot management devices within the market.
  • The United States commands a dominant position in the global clot management devices market.
  • Company Profiles: Detailed analysis of the major companies present in Global Clot Management Devices Market.

New Resource from National Comprehensive Cancer Network Breaks the Silence on Common but Lesser-Known Cause of Cancer Deaths

Retrieved on: 
星期四, 九月 7, 2023
Pancreatic cancer, Sidney Kimmel, VTE, Surgeon, Thrombus, Journal of the National Comprehensive Cancer Network, Pulmonary embolism, Neoplasm, Multiple myeloma, Graft-versus-host disease, Risk assessment, Chest pain, National Comprehensive Cancer Network, Thrombosis, Cardiology, Immunotherapy, Visit, NCCN, Radiology, Vomiting, Pancreatic serous cystadenoma, Anticoagulant, Back pain, Pharmacist, Estate (law), Coronary thrombosis, Guideline, Patient, Amazon (company), Sidney Kimmel Comprehensive Cancer Center, Risk, Swelling, Anemia, Disease, FACS, Nausea, Johns Hopkins, Research, Health, Death, Red, Education, Caregiver, Content, Birth control, Cancer, MD

PLYMOUTH MEETING, Pa., Sept. 7, 2023 /PRNewswire/ -- The National Comprehensive Cancer Network (NCCN®) today announced the publication of a new supportive care patient guideline focused on preventing and treating cancer-associated blood clots, also known as venous thromboembolism (VTE). Research shows that people with cancer are nine times more likely to experience blood clots than those without cancer. Blood clots are a leading cause of death for people with cancer, second only to the direct effects of the cancer itself.1,2

Key Points: 
  • Research shows that people with cancer are nine times more likely to experience blood clots than those without cancer.
  • Blood clots are a leading cause of death for people with cancer, second only to the direct effects of the cancer itself.1,2
    Research shows that people with cancer are nine times more likely to experience blood clots than those without cancer.
  • "Cancer is a strong risk factor for developing a blood clot, and thrombosis is the second leading cause of death in patients with cancer.
  • Preventing and treating blood clots is also discussed in several relevant disease-specific NCCN patient guidelines, including for pancreatic cancer, multiple myeloma, and myeloproliferative neoplasms.

Imperative Care Unveils New Structure to Elevate Care for Patients with Vascular Diseases

Retrieved on: 
星期四, 八月 10, 2023
Medical Devices, Health, Health Technology, Other Health, Cardiology, Biotechnology, Survivor, Stroke, Vein, Pulmonary embolism, Multimedia, Medicine, Jacobs Institute for Design Innovation, Thrombectomy, Hospital, Patient, Physician, Prodigy, Reperfusion, Robotics, FDA, Inception, Moyamoya disease, Automation, Pharmaceutical industry, Nursing

The company was founded with a singular focus on transforming stroke care from detection through recovery and making better treatment available to more patients.

Key Points: 
  • The company was founded with a singular focus on transforming stroke care from detection through recovery and making better treatment available to more patients.
  • This focus has since expanded to develop treatments for other devastating ischemic diseases, such as pulmonary embolism and peripheral vascular disease.
  • Imperative Care is now the parent company of four businesses that share a common purpose to bring more care to more people affected by stroke and other ischemic diseases.
  • Imperative Care Vascular (formerly TRUVIC Medical, which was acquired by Imperative Care in 2021), a business unit advancing innovative treatments for people suffering from devastating vascular diseases, including pulmonary embolism.